Catching the therapeutic window of opportunity in early crohn’s disease

Silvio Danese, Gionata Fiorino, Carlos Fernandes, Laureal Peyrin-Biroulet

Research output: Contribution to journalArticle

Abstract

Crohn’s disease (CD) is a chronic, disabling, progressive and destructive disease. The general goal of conventional step-up strategy in CD treatment is to treat and control symptoms. This strategy did not change the disease course and is now being replaced with a treat-to-target approach. Achieving deep remission (clinical remission and absence of mucosal ulcerations) is the target in CD in 2014. Inducing and maintaining deep remission is needed to prevent long-term outcomes such as bowel damage and disability in CD. Diagnostic delay is a common issue in CD and is associated with an increased risk of bowel damage over time. Identification of poor prognostic factors, risk stratification together with the development of “red flags” may result in early intervention with disease-modifying agents such as anti-TNF agents with the final aim of preventing overtreatment and avoiding undertreatment. Similar to rheumatoid arthritis, by catching the therapeutic window of opportunity in early CD and achieving deep remission, this could be the best way to change disease course (hospitalizations, surgeries, bowel damage, and disability) and patients’ life.

Original languageEnglish
Pages (from-to)1056-1063
Number of pages8
JournalCurrent Drug Targets
Volume15
Issue number11
Publication statusPublished - Jan 1 2014

    Fingerprint

Keywords

  • Crohn’s disease
  • Early disease
  • Inflammatory bowel disease
  • Therapy

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this